Want to see NCNA full AI Analyst Report?
NCNA Stock Chart & Stats
$1.53
-$0.03(-2.33%)
At close: 4:00 PM EDT
$1.53
-$0.03(-2.33%)
Day’s Range― - ―
52-Week Range$0.95 - $4.55
Previous Close$1.26
Volume26.65K
Average Volume (3M)178.88K
Market Cap
$4.15M
Enterprise Value-$18.63M
Total Cash (Recent Filing)$19.39M
Total Debt (Recent Filing)$667.94K
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.97
Shares Outstanding4,161,971
10 Day Avg. Volume45,080
30 Day Avg. Volume178,876
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-4.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit261.06
Enterprise Value/Ebitda1.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Intellectual PropertyThe European composition-of-matter patent strengthens protection for NUC-7738 alongside existing U.S. and China grants. Broad patent coverage can preserve exclusivity, support future partnering or commercialization, and improve NuCana’s competitive position as clinical development advances.
Low LeverageVery low leverage limits direct balance-sheet debt risk and avoids substantial interest obligations while the company funds oncology research. This gives management more financial flexibility than a highly indebted biotech, although it does not remove the need for future financing.
Improving Cash BurnThe reduction in operating cash outflow indicates improving cost control and a slower rate of cash depletion than in earlier periods. If maintained, this trend could extend the funding runway and provide more time to reach clinical milestones, despite continued negative cash generation.
Bears Say
No RevenueNuCana remains pre-revenue, so its business has not yet demonstrated commercial demand or internally generated funding. Continued dependence on clinical progress before product sales creates a long path to self-sustaining operations and leaves future value tied to pipeline execution.
Persistent Cash BurnPersistent negative operating and free cash flow means the company is not self-funding its research and development activities. Ongoing cash consumption can require additional financing before commercialization, creating continuing liquidity pressure and potential constraints on development plans.
Shrinking Equity BaseThe substantial reduction in shareholders’ equity reflects cumulative value erosion from ongoing losses and leaves a smaller capital base supporting the business. A shrinking equity cushion reduces resilience during prolonged development and can increase dependence on external funding over time.
Nucana News
NCNA FAQ
What was Nucana Plc’s price range in the past 12 months?
Nucana Plc lowest stock price was $0.95 and its highest was $4.55 in the past 12 months.
What is Nucana Plc’s market cap?
Nucana Plc’s market cap is $4.15M.
When is Nucana Plc’s upcoming earnings report date?
Nucana Plc’s upcoming earnings report date is Nov 12, 2026 which is in 21 days.
How were Nucana Plc’s earnings last quarter?
Nucana Plc released its earnings results on Aug 13, 2026. The company reported $0 earnings per share for the quarter.
Is Nucana Plc overvalued?
According to Wall Street analysts Nucana Plc’s price is currently Overvalued.
Does Nucana Plc pay dividends?
Nucana Plc does not currently pay dividends.
What is Nucana Plc’s EPS estimate?
Nucana Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nucana Plc have?
Nucana Plc has 4,161,971 shares outstanding.
What happened to Nucana Plc’s price movement after its last earnings report?
Nucana Plc reported an EPS of $0 in its last earnings report. Following the earnings report the stock price went up 7.432%.
Which hedge fund is a major shareholder of Nucana Plc?
Currently, no hedge funds are holding shares in NCNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nucana Plc
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
1.49% Other Institutional Investors
98.51% Public Companies and
Individual Investors